CA3011289A1 - Compounds for inhibiting cancer and virus - Google Patents
Compounds for inhibiting cancer and virus Download PDFInfo
- Publication number
- CA3011289A1 CA3011289A1 CA3011289A CA3011289A CA3011289A1 CA 3011289 A1 CA3011289 A1 CA 3011289A1 CA 3011289 A CA3011289 A CA 3011289A CA 3011289 A CA3011289 A CA 3011289A CA 3011289 A1 CA3011289 A1 CA 3011289A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- compound
- pharmaceutically acceptable
- solvate
- enantiomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277653P | 2016-01-12 | 2016-01-12 | |
| US62/277,653 | 2016-01-12 | ||
| PCT/US2017/013253 WO2017123809A1 (en) | 2016-01-12 | 2017-01-12 | Compounds for inhibiting cancer and virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3011289A1 true CA3011289A1 (en) | 2017-07-20 |
Family
ID=59311465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3011289A Abandoned CA3011289A1 (en) | 2016-01-12 | 2017-01-12 | Compounds for inhibiting cancer and virus |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10745433B2 (https=) |
| EP (1) | EP3402800A4 (https=) |
| JP (1) | JP2019506382A (https=) |
| CN (1) | CN108884123A (https=) |
| CA (1) | CA3011289A1 (https=) |
| TW (1) | TWI638825B (https=) |
| WO (1) | WO2017123809A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017223491A1 (en) * | 2016-06-23 | 2017-12-28 | Health Research, Inc. | Pharmaceutical compositions with antiflaviviral activity |
| US11384114B2 (en) | 2016-12-09 | 2022-07-12 | Warsaw Orthopedic, Inc. | Polymorphic forms of an oxysterol and methods of making them |
| CN111518147A (zh) * | 2020-04-29 | 2020-08-11 | 华东理工大学 | 苯甲酰苯胺类化合物及在制备铜绿假单胞菌抑制剂的增敏剂中的应用 |
| US11767303B2 (en) | 2020-07-24 | 2023-09-26 | Health Research, Inc. | Compounds and methods for inhibiting viral replication and methods of treating and preventing flaviviral infections |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE150471C (https=) * | ||||
| DD150471A1 (de) * | 1979-07-02 | 1981-09-02 | Konrad Schwabe | Verfahren zur herstellung von 5-bromsalizyl-4'-chloranilid-0-glykosiden |
| US6555519B2 (en) * | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| CA2488363C (en) * | 2002-06-06 | 2011-01-04 | Institute Of Medicinal Molecular Design, Inc. | O-substituted hydroxyaryl derivatives |
| AU2003249244A1 (en) * | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| TW200529812A (en) | 2003-12-26 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Benzamide derivatives |
| WO2008033466A2 (en) * | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
| US8211882B2 (en) | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
| ES2647072T3 (es) | 2011-04-18 | 2017-12-19 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Niclosamida para el tratamiento de la metástasis en el cáncer |
| WO2014023329A1 (en) | 2012-08-06 | 2014-02-13 | Life And Brain Gmbh | Niclosamide and its derivatives for use in the treatment of solid tumors |
| WO2014113467A1 (en) | 2013-01-15 | 2014-07-24 | Board Of Regents, The University Of Texas System | Stat3 inhibitor |
| CN103130696B (zh) * | 2013-03-21 | 2014-06-11 | 山东大学 | 邻氨基苯甲酰胺类化合物及其制备方法与应用 |
| CN104771386A (zh) | 2014-01-10 | 2015-07-15 | 中国科学院广州生物医药与健康研究院 | 苯甲酰胺类化合物及其应用 |
-
2017
- 2017-01-12 CN CN201780006499.9A patent/CN108884123A/zh active Pending
- 2017-01-12 CA CA3011289A patent/CA3011289A1/en not_active Abandoned
- 2017-01-12 TW TW106101068A patent/TWI638825B/zh not_active IP Right Cessation
- 2017-01-12 JP JP2018536167A patent/JP2019506382A/ja active Pending
- 2017-01-12 WO PCT/US2017/013253 patent/WO2017123809A1/en not_active Ceased
- 2017-01-12 EP EP17738972.3A patent/EP3402800A4/en not_active Withdrawn
- 2017-01-12 US US16/069,100 patent/US10745433B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3402800A4 (en) | 2019-11-13 |
| WO2017123809A1 (en) | 2017-07-20 |
| TW201734028A (zh) | 2017-10-01 |
| EP3402800A1 (en) | 2018-11-21 |
| TWI638825B (zh) | 2018-10-21 |
| JP2019506382A (ja) | 2019-03-07 |
| CN108884123A (zh) | 2018-11-23 |
| US10745433B2 (en) | 2020-08-18 |
| US20190016743A1 (en) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11084786B2 (en) | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | |
| ES2504690T3 (es) | Compuestos inhibidores de PARP, composiciones y métodos de uso | |
| CN103958502B (zh) | 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物 | |
| CN102548558B (zh) | 具有Aurora A选择性抑制作用的氨基吡啶衍生物 | |
| CN105837586B (zh) | 二噁烷并喹唑啉胺类化合物及其制备方法和作为表皮生长因子受体抑制剂的应用 | |
| EP3324954B1 (en) | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | |
| US10745433B2 (en) | Compounds for inhibiting cancer and virus | |
| JPWO2018117177A1 (ja) | Brk阻害化合物 | |
| WO2022199627A1 (en) | Polycyclic compounds and uses thereof | |
| CN102438626B (zh) | 具有Aurora A选择性抑制作用的新型氨基吡啶衍生物 | |
| CN116323590A (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| CN103509030A (zh) | 喜树碱类化合物及其制备和用途 | |
| CN115707704B (zh) | 氘代稠合三环类化合物及其组合物和用途 | |
| TWI684581B (zh) | 與泛素化-蛋白酶體系統有關之化合物及醫藥組合物 | |
| CN103626761B (zh) | 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用 | |
| US11795179B2 (en) | Discovery of imidazothiazole- and imidazooxazole-based selective HER4 kinase inhibitors as potential anticancer agents | |
| WO2018167187A1 (en) | 5-carboxamide-2-thiobarbituric acids and use thereof as medicaments | |
| WO2022171018A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| ES2702698T3 (es) | Polimorfo del derivado de dihidropirazolopirimidinona como inhibidor de la cinasa Wee1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220712 |